Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes

Diabetes and Metabolism

Volumn 40, Issue 4, 2014, Pages 284-291

  Bounthavong, M ^a   Tran, J N ^b   Golshan, S ^c   Piland, N F ^d   Morello, C M ^e   Blickensderfer, A ^f   Best, J H ^f,g  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b OPTUM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IDAHO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Detemir; Exenatide; Glargine; Long acting insulin analogs; Pharmacoepidemiology; Retrospective cohort; Type 2 diabetes; Veterans

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VETERANS HEALTH; WEIGHT REDUCTION; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; VETERAN;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; UNITED STATES; VENOMS; VETERANS; VETERANS HEALTH;

EID: 84927174916     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.06.002     Document Type: Article

References (23)

1. Centers for Disease Control Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
2. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008, 26:77-82.
3. Quality Enhancement Research Initiative Diabetes Quality Enhancement Research Initiative [Internet] 2013, US Department of Veterans Affairs, Washington D.C., USA, Available from: http://www.queri.research.va.gov/dm/ [cited 2013 Apr 24].
4. Miller D.R., Safford M.M., Pogach L.M. Who has diabetes? Best estimates of diabetes prevalence in the department of veterans affairs based on computerized patient data. Diabetes Care 2004, 27(SUPPL. 2):b10-b21.
5. Reiber G.E., Koepsell T.D., Maynard C., Haas L.B., Boyko E.J. Diabetes in nonveterans, veterans, and veterans receiving department of veterans affairs health care. Diabetes Care 2004, 27(SUPPL. 2):b3-b9.
6. Maciejewski M.L., Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the veterans administration. Diabetes Care 2004, 27(SUPPL. 2):b69-b73.
7. Owens D.R. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011, 13(SUPPL. 1):S5-S14.
8. Singh S.R., Ahmad F., Lal A., Yu C., Bai Z., Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180:385-397.
9. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
10. 1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide. Diabetes Obes Metab 2012, 14:826-834.
11. Moretto T.J., Milton D.R., Ridge T.D., Maconnell L.A., Okerton T., Wolka A.M., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
12. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
13. Buse J.B., Bergenstal R.M., Glass L.C., Heilmann C.R., Lewis M.S., Kwan A.Y., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
14. Bunck M.C., Eliasson B., Cornér A., Heine R.J., Shaginian R.M., Taskinen M.R., et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:374-377.
15. VA Information Resource Center VIReC resource guide: VA corporate data warehouse 2012, U.S. Dept. of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center, Hines, IL.
16. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
17. Farmer A.J., Perera R., Ward A., Heneghan C., Oke J., Barnett A.H., et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ 2012, 344:e486.
18. Clar C., Barnard K., Cummins E., Royle P., Waugh N. Aberdeen Health Technology Assessment Group. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010, 14:1-140.
19. Tsui E., Barnie A., Ross S., Parkes R., Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001, 24:1722-1727.
20. Pawaskar M., Li Q., Hoogwerf B.J., Reynolds M.W., Lee L.J., Fonseca V. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. Endocr Pract 2012, 18:700-711.
21. Keyvanara M., Hosseini S.M., Emami P. Study of the relationship between socioeconomic status and controlling diabetes among patients admitted to specialized clinic of Dr Gharazi hospital in Isfahan-2011. J Educ Health Promot 2012, 1:28.
22. Sundquist K., Chaikiat A., León V.R., Johansson S.-E., Sundquist J. Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes Metab Res Rev 2011, 27(3):244-254.
23. Pencek R., Blickensderfer A., Li Y., Brunell S.C., Anderson P.W. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med 2012, 124:21-32.